Stock Spotlight: Pro Medicus Limited (ASX:PME)
This week's Stock Spotlight is ASX-listed Pro Medicus Limited.
About Pro Medicus Limited.
Pro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe. The company offers Visage RIS Visage 7 Enterprise Imaging Platform, a healthcare imaging software that provides radiologists, physicians, and clinicians with access and visualization capability for viewing 2-D, 3-D, and 4-D medical images; and picture archive and communication system (PACS)/digital imaging software. It also provides Visage RIS, a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform for secure email and integration products. In addition, the company offers Visage Ease, a mobile application that provides users access to medical imaging results; and Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.
Source: EODHD
Key Stats
Key Stats
Source: EODHD. Data as of 16/02/26.
Price Performance
Growth Potential
- Strong balance sheet position with no debt (cash on hand $221.8m)
- Proven and market leading technology (management believes they are 24 months ahead of competitors), with PME’s product commanding a price premium.
- New contract wins (more win rates plus higher value per contract), increasing usage by existing clients and winning market share in the U.S. (penetration is just 10% with Visage able to address 100% of TAM from a product perspective).
- Quick to implement is a competitive advantage for PME which reduces the barrier to change. Previously companies could take up to 2.5 years to complete an implementation, whereas PME can do it in weeks/months.
- New product launches – Enterprise Imaging solutions and moving into other “ologies” such as cardiology and ophthalmology. Developing artificial intelligence (AI) capabilities. Management noted cardiology opportunity could be approx. 15-20% size of radiology total addressable market (by value).
- Leveraged to the digital health data thematic and industry’s transition to cloud.
- Expansion into new geographies and potential M&A activity.
Key Risks
- High valuation which subjects the stock price to more volatility.
- Timing (long lead time to close contracts) and scale of new contract wins disappoint relative to market expectations.
- Contract renewals (price pressure) and potential budget cuts at hospitals leading to the delay of software upgrades / investment.
- Increasing competitive pressures
- Systems reliability – data breach or drop in quality.
- Regulatory / funding changes – reimbursement changes.
- Key management risks – CEO Sam Hupert (including the large shareholding of the founders)
Subscribe to our newsletter
Disclaimer: This article does not constitute financial advice nor a recommendation to invest in the securities listed. The information presented is intended to be of a factual nature only. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing.
